Recombinant human interferon-α1b inhibits SARS-CoV-2 better than interferon-α2b in vitro

• A comprehensive evaluation method for anti-SARS-CoV-2 drugs was established based on qPCR, TCID(50), and immunofluorescence. • A significant antiviral effect of rHuIFN-α1b was shown in Vero and Calu-3 ​cells. • rHuIFN-α1b has a good potential in the application of anti-COVID-19 therapy.

Detalles Bibliográficos
Autores principales: Shi, Danrong, Chen, Keda, Lu, Xiangyun, Cheng, Linfang, Weng, Tianhao, Liu, Fumin, Wu, Nanping, Li, Lanjuan, Yao, Hangping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wuhan Institute of Virology, Chinese Academy of Sciences 2022
Materias:
Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8786678/
https://www.ncbi.nlm.nih.gov/pubmed/35597770
http://dx.doi.org/10.1016/j.virs.2022.01.031
Descripción
Sumario:• A comprehensive evaluation method for anti-SARS-CoV-2 drugs was established based on qPCR, TCID(50), and immunofluorescence. • A significant antiviral effect of rHuIFN-α1b was shown in Vero and Calu-3 ​cells. • rHuIFN-α1b has a good potential in the application of anti-COVID-19 therapy.

Ejemplares similares